ResMed
ResMed Inc. (NYSE: RMD) develops medical devices, diagnostics and digital health software for sleep and breathing disorders, alongside software for residential care providers. Its Sleep and Breathing Health segment offers CPAP and bilevel devices, ventilators, masks, home sleep-testing products and connected-care… From the company’s description.
In fiscal 2026, ResMed reported revenue of $5.65B, up 9.9% from fiscal 2025, and net income of $1.52B. Its operating margin was 33.4%, and operations generated $1.81B in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure.
What ResMed does
In the company’s own words
ResMed Inc. (NYSE: RMD) develops medical devices, diagnostics and digital health software for sleep and breathing disorders, alongside software for residential care providers. Its Sleep and Breathing Health segment offers CPAP and bilevel devices, ventilators, masks, home sleep-testing products and connected-care applications for conditions including obstructive sleep apnea and chronic respiratory disease; customers include patients, clinicians, hospitals and home medical equipment providers. Brands and platforms include AirSense, AirCurve, AirMini, AirView and myAir, as well as the Nidra wearable device for restless legs syndrome. Its Residential Care Software segment provides billing, electronic health records, analytics and care-management tools to home medical equipment, home health, hospice, nursing and senior-living providers; this segment accounts for approximately 12% of net revenue. ResMed sells through subsidiaries and distributors in more than 140 countries and employs approximately 11,370 people. The company began in 1989 with CPAP technology and has expanded through product development and acquisitions, including VirtuOx and Noctrix. Its website is www.resmed.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- June
- CIK
- 943819
- SIC
- 3841
Financial performance, year by year
Fiscal 2012–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ResMed — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in ResMed · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · ResMed’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ResMed and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ResMed's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ResMed's last four quarterly filings that the numbers alone won't show?”